First-Line Ibrutinib Plus Venetoclax for Nonblastoid Mantle Cell Lymphoma in Patients ≥ 65 Years Old or With TP53 Mutations Authors: Michael Wang, MD; Marc S. Hoffmann, MD; Tomasz Wróbel, MD, PhD; Marek Trněný, MD; David Belada, MD, PhD; Fatih Demirkan, MD; Panayiotis Panayiotidis, MD, PhD; Wojciech Jurczak, MD, PhD; Pier Luigi Zinzani, MD, PhD; Mary-Margaret Keating, MD; Sung-Soo Yoon, MD, PhD; Miklós Egyed, MD, PhD; Constantine S. Tam, MD, MBBS; Nathalie A. Johnson, MD, PhD; Edith Szafer-Glusman, PhD; Jennifer Lin, MS, MA; James P. Dean, MD, PhD; Jutta K. Neuenburg, MD, PhD; Gottfried von Keudell, MD, PhD

https://www.medscape.org/viewarticle/first-line-ibrutinib-plus-venetoclax-nonblastoid-mantle-cell-2026a1000xwe?page=1